Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has established a holding company Eisai China Holdings Ltd. in Suzhou, Jiangsu Province, China. Eisai China Holdings Ltd. is a subsidiary of Eisai Asia Regional Services Pte. Ltd. which is Eisai's representative subsidiary for Asia located in Singapore.

With the establishment of this new company, Eisai China Holdings Ltd. will integrate the Chinese domestic subsidiaries Eisai China Inc. and Eisai (Suzhou) Trading Co. Ltd., strengthen various functions including accounting, legal and compliance, and also create a flexible capital transfer system to respond to capital demands, in order to optimize the management of business in China.

The Chinese pharmaceutical market is the second largest in the world after the United States, and is expected to achieve strong double digit growth into the future.1 Through the establishment of Eisai China Holdings Ltd., Eisai plans to further enhance its pharmaceutical production, sales and supply systems in China, and through the stable supply of high quality pharmaceutical products together with the provision of accurate information, strives to fulfill the diverse needs of patients and their families in China.

< Outline of New Subsidiary >

*You can scroll to the left or right here

Company Name: Eisai China Holdings Ltd.
Location: Suzhou, Jiangsu Province, China
Representative: Norio Kaneko, Chairman of the Board; Wenqin Yue, President
Scope of Business: Planning and execution of strategy, consolidated finance and accounting, internal auditing
Charter Capital: 30 million U.S. dollars
Date Established: November 11, 2014
Operations Commenced: December 1, 2014

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.


< Notes to editors >

1. About the Chinese pharmaceutical market

Due to various factors including population growth, the aging of the population and the implementation of a public healthcare system, the Chinese pharmaceutical market is exhibiting strong growth. In 2013, the size of the market was valued at 86.8 billion U.S dollars (approximately 9.1 trillion yen), and grew 16% compared to the previous year.2 While policies to reduce drug prices have been promoted in order to reduce healthcare expenditure, healthcare needs are rising due to the expansion of the middle class, and the Chinese pharmaceutical market is expected to achieve strong double digit growth into the future (expected compound annual growth rate 12.9% over the 5-year period from 2014).1

2. About Eisai's subsidiaries in China

1)Eisai China Inc.

*You can scroll to the left or right here

Location: Suzhou, Jiangsu Province, China
Representatives: Yoshiyuki Ose, Chairman of the Board; Yanhui Feng, President
Scope of Business: Manufacture and sales of pharmaceutical products
Charter Capital: 78.54 million U.S. dollars
Date of Establishment: March 1996

2)Eisai (Suzhou) Trading Co., Ltd.

*You can scroll to the left or right here

Location: Suzhou, Jiangsu Province, China
Representative: Yanhui Feng, Executive Director and President
Scope of Business: Wholesale, import and export of active pharmaceutical ingredients, pharmaceutical formulations and biopharmaceuticals, intermediate trade, etc.
Charter Capital: 700 million Chinese yuan
Date of Establishment: October 2010
  • 1
    ©2014 IMS Health, Forecasting to 2018: Outlook for the Pharmaceutical Markets in the UK, China and Japan, reproduction prohibited
  • 2
    ©2014 IMS Health, IMS World Review Analyst, reproduction prohibited